Do We Need the Largest LLMs for Every Clinical Decision?

Abstract

Large clinical language models often require multi-GPU infrastructure, limiting local deployment. We introduce CERTA, a decision-level statistical certificate that determines when a quantized model may substitute for its native BF16 reference and escalates decisions that cannot be certified to it. Across eleven instruction-tuned models, both general-purpose and domain-adapted, from three families (7-72B), we evaluated 2,500 clinical-verification decisions from de-identified patient contexts (2,484 patients), with patient-disjoint calibration and testing. In the higher-power operational analysis, round-to-nearest 8-bit quantization at BF16 storage served 99.8-100% of held-out decisions across all eleven models; formal finite-sample guarantees were assessed separately using the exact split-sample procedure. In the same operational analysis, the class-conditional 4-bit frontier reduced the amortized, BF16-equivalent deployment cost to 25.8% and 27.3% of the BF16 reference for Qwen2.5-72B and HuatuoGPT-o1-72B, respectively, with measured peak memory of 43.0 and 42.7 GB, below the nominal capacity of a single 48 GB accelerator. Deployment on that specific hardware was not directly tested. Under the exact split-sample certificate, which also accounts for configuration selection, these costs were 26.7% and 27.9%. On external disease named-entity benchmarks against human annotations, the frontier-selected NF4 configurations had a mean absolute F1 change of 0.045 on both datasets, with substantial model-specific variation. CERTA converts compression from a fixed precision choice into a risk-controlled deployment policy for this verification task.

Abstract: arXiv descriptive metadata (CC0). Thank you to arXiv for use of its open access interoperability. This service was not reviewed or approved by, nor does it necessarily express or reflect the policies or opinions of, arXiv.